U.S. CLINICAL TRIAL OF ACELLULAR PERTUSSIS VACCINE

这项临床试验将比较三批无细胞百日咳 互相接种疫苗。此外，审判的第四个分支将 利用目前的全细胞疫苗。审判的所有四个分支都将 使用与白喉和破伤风相结合的百日咳疫苗。这个 承包商将随机招募约2000名受试者 被分配到审判的四个分支之一。免疫接种将是 分别在2个月、4个月和6个月给药。反应将受到监控 通过分别在24小时、72小时和168小时后拨打的跟踪电话 免疫接种。这些数据将与其他数据一起进行分析 合作者来确定安全性。

This clinical trial will compare three lots of acellular pertussis vaccine with each other. In addition, a fourth arm of the trial will utilize the current whole cell vaccine. All four arms of the trial will utilize a pertussis vaccine combined with diphtheria and tetanus. The Contractor will recruit approximately 2000 subjects who will be randomly assigned to one of the four arms of the trial. Immunizations will be administered at two, four and six months. Reactions will be monitored by follow-up phone calls made at 24, 72 and 168 hours after each immunization. The data will be analyzed in conjunction with the other collaborators to determine the safety.